Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danqi Qinghua Granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. The name is derived from its primary components, *Salvia miltiorrhiza* (Danshen) and *Astragalus membranaceus* (Huangqi), combined with herbs intended to "clear heat and transform dampness" (Qinghua). It is primarily investigated for the treatment of type 2 diabetes mellitus in patients who are overweight or obese. The formulation is designed to address the TCM patterns of Qi deficiency and internal heat-dampness, which are clinically associated with insulin resistance and metabolic syndrome. It is currently being evaluated in interventional clinical trials to assess its efficacy in improving glycemic control and reducing body mass index.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danqi qinghua granules.